Suresh Muthukumaraswamy
@sdmuthu.bsky.social
Researcher at University of Auckland.
Ivory tower inhabitant.
Views are mine.
https://scholar.google.co.uk/citations?user=VU4GTNsAAAAJ&hl=en&oi=ao
Ivory tower inhabitant.
Views are mine.
https://scholar.google.co.uk/citations?user=VU4GTNsAAAAJ&hl=en&oi=ao
The trial data for CYB003 have clear problems- even if you look at just what is available. The placebo group only shows a 6-7 MADRS score drop. Typically you would expect double that in an AD trial (depends on trial contingencies). Most likely the placebo group is unblinded.
November 19, 2024 at 7:49 AM
The trial data for CYB003 have clear problems- even if you look at just what is available. The placebo group only shows a 6-7 MADRS score drop. Typically you would expect double that in an AD trial (depends on trial contingencies). Most likely the placebo group is unblinded.